<DOC>
	<DOCNO>NCT01470495</DOCNO>
	<brief_summary>RFA routaine treatment recurrent HCC . Recently Sorafenib report promising drug treat late stage HCC . But study related effectiveness recurrent HCC . So investigator hypothesize combined RFA Sorafenib might reduce frequency recurrence improve overall survival disease free survial .</brief_summary>
	<brief_title>Combined Treatment RFA Sorafenib Recurrent HCC</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>recurrent HCC curative resection without gender restriction age 18 75 year The liver function show bad ChildPugh B tumor node le 5cm 3 nodule Pregnancy patient With extrahepatic tumor lymphnode metastasis Tumor invasion thrombosis portal vein , hepatic vein inferior vena cava</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>